Cosentyx (secukinumab) has been approved by the US Food and Drug Administration for adults with polymyalgia rheumatica whose disease has not responded well enough to corticosteroids or who cannot tolerate a steroid taper, Novartis announced on 17 November 2026. It is the first anti-IL-17 biologic approved for the condition and is already authorised in the EU.
The decision rests on the phase 3 REPLENISH trial, in which Cosentyx doubled the rate of sustained remission compared with placebo at one year, with less steroid use. Novartis says this is the 11th US indication for Cosentyx. In Europe, the European Commission approved the same use in October, and the trial had one site in Dublin.
- Decision: FDA approval of Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica (PMR), announced by Novartis on 17 November 2026.
- Who it covers: adults who have had an inadequate response to corticosteroids or who cannot tolerate a corticosteroid taper.
- Evidence: the REPLENISH trial of 381 patients in 27 countries. Novartis reports sustained remission at week 52 in 40.5% of patients on Cosentyx 150 mg against 20.5% on placebo.
- Europe: the European Commission approved Cosentyx for PMR on 21 October 2026, after a positive CHMP opinion on 18 September 2026.
- Ireland: REPLENISH listed one Irish site, in Dublin. Cosentyx is reimbursed in Ireland for psoriasis, psoriatic arthritis and axial spondyloarthritis, but no NCPE assessment for PMR is listed.
What has the FDA approved?
Novartis says the FDA approved Cosentyx 150 mg for "adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids" or who cannot tolerate a corticosteroid taper. The company describes it as the first and only anti-IL-17 biologic approved for PMR. Cosentyx is an antibody that blocks interleukin-17A, a signalling protein involved in inflammation, and is already used for psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa.
The US release does not give a launch date, price or the full dosing schedule for PMR. Novartis says about 966,000 people in the US live with PMR. Cosentyx is not the first biologic for PMR in the US: BioPharm International notes that Kevzara (sarilumab), an IL-6 blocker, was approved by the FDA for PMR in February 2023. Our secukinumab page lists current trials of the medicine.
What is polymyalgia rheumatica?
PMR is an inflammatory condition that causes pain and stiffness in the shoulders, neck and hips. The NHS says the main symptom is "muscle stiffness in the morning that lasts longer than 45 minutes". Most people diagnosed are over 65, it is very rare under 50, and it is more common in women. Tiredness, loss of appetite and weight loss are also common.
The NHS also says up to 1 in 5 people with PMR develop giant cell arteritis, an inflammation of arteries in the head and neck that needs urgent treatment because it can cause stroke or blindness.
Why do patients need options beyond steroids?
The standard treatment is a steroid, usually prednisolone, started at a moderate dose and then slowly reduced. The NHS says most people "will need a course of steroid treatment that lasts for 12 months to 2 years". Novartis says relapses are frequent, affecting up to 40% of patients in the first year, and that long-term steroid use is linked to osteoporosis, cardiovascular disease and diabetes. Many people with PMR are older adults who are already at higher risk of these problems.
Prof John Stone of Harvard Medical School and Massachusetts General Hospital, the global principal investigator for REPLENISH, said: "For too long, treatment options beyond glucocorticoids have been limited." He added that "secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids."
What did the REPLENISH trial show?
REPLENISH (NCT05767034) was a double-blind, placebo-controlled phase 3 trial that enrolled 381 adults aged 50 and over with PMR, according to ClinicalTrials.gov. Patients were randomised in equal groups to Cosentyx 300 mg, Cosentyx 150 mg or placebo, every four weeks, and all three groups followed the same 24-week steroid taper. The main goal was sustained remission at week 52: being in remission at week 12 and staying free of a flare needing extra treatment through to week 52.
The results were published in the New England Journal of Medicine and presented at the EULAR 2026 congress on 3 June 2026. Novartis gave these figures:
| Measure | Result |
|---|---|
| Sustained remission, Cosentyx 300 mg | 41.2% (P < 0.001 against placebo) |
| Sustained remission, Cosentyx 150 mg | 40.6% in the published data; 40.5% in the FDA approval release |
| Sustained remission, placebo | 20.4% in the published data; 20.5% in the FDA approval release |
| Mean adjusted yearly steroid dose, 300 mg / 150 mg | 1,604 mg / 1,683 mg |
| Mean adjusted yearly steroid dose, placebo | 2,093 mg |
| Serious adverse events, 150 mg against placebo | 15.9% against 14.2% |
Novartis says all secondary goals were met, including complete sustained remission and time to first escape or rescue treatment. Its releases do not give the figures for those measures.
What are the safety findings?
Novartis says the safety results were consistent with the known profile of Cosentyx. In its FDA release, hypersensitivity reactions such as eczema, dermatitis, rash and hives were reported in 14% of patients on Cosentyx 150 mg against 9% on placebo, and urinary tract infections in 13% against 7%. The company also reports one serious urinary tract infection and one fatal case of cryptococcal meningitis, a fungal infection, in patients treated with Cosentyx. Patients should discuss the risks and benefits with their rheumatologist.
Where does Cosentyx stand in Europe?
Europe moved first. The CHMP, the European Medicines Agency's medicines committee, gave a positive opinion on 18 September 2026, and Novartis announced European Commission approval on 21 October 2026. The EU wording covers adults with PMR who have had an inadequate response to glucocorticoids or who relapse during a glucocorticoid taper.
According to Novartis's EU release, the recommended EU dose is 150 mg by injection under the skin at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance, alongside a steroid taper. Cosentyx can then continue on its own, and the maintenance dose can be raised to 300 mg depending on clinical response. Prof Christian Dejaco, Director of the Department of Rheumatology at the South Tyrol Health Trust in Bruneck, Italy, described the EU decision as an important advance. A review is also under way in Japan.
Did the trial run in Ireland?
Yes. The ClinicalTrials.gov record for REPLENISH lists one Irish site, a Novartis investigative site in Dublin, out of 132 sites in 26 countries. The trial's other European sites included France, Germany, Italy, Spain, Czechia, Denmark and the Netherlands, with three sites in the United Kingdom. The open-label extension study, REPLENISH-EXT (NCT06331312), lists 85 sites and none in Ireland.
Novartis has been in Ireland since the 1950s and describes itself as one of the first pharmaceutical companies to locate here. Novartis Ireland Limited is based at Sandyford Business Park in Dublin, which also houses the Novartis Corporate Center.
Will Cosentyx be funded for PMR in Ireland?
That is not yet known. EU approval allows Cosentyx to be prescribed for PMR in Ireland, but public funding for a new indication needs an HSE decision. Novartis Ireland says Cosentyx is already reimbursed here for adult plaque psoriasis, psoriatic arthritis and axial spondyloarthritis, and that some uses in the label, including non-radiographic axial spondyloarthritis, are not reimbursed under the HSE scheme.
The National Centre for Pharmacoeconomics (NCPE) lists earlier secukinumab assessments for psoriasis, psoriatic arthritis and ankylosing spondylitis. For psoriatic arthritis, it completed a rapid review in December 2015 and the HSE approved reimbursement after confidential price talks. The NCPE site shows no entry for secukinumab in PMR at the time of writing. Our guide to autoimmune medicines in Ireland explains the wider picture.
Frequently asked questions
What is Cosentyx?
Cosentyx is the brand name of secukinumab, a Novartis antibody that blocks interleukin-17A. It is given by injection and is used for several inflammatory diseases.
Does Cosentyx replace steroids in PMR?
Not at the start. In REPLENISH it was given alongside a 24-week steroid taper, and the approval covers people who have not responded well enough to steroids or cannot tolerate tapering them.
Which dose is approved in the US?
The 150 mg dose. The US release does not give the full schedule. In the EU, 150 mg is given weekly for five weeks and then monthly.
Is it available for PMR in Ireland?
It is authorised in the EU, which includes Ireland, but HSE reimbursement for PMR has not been assessed yet.
Outlook
The next steps are the Japanese review, the US launch and longer-term safety data from REPLENISH-EXT, which is due to finish in 2028. In Ireland, the key question is whether Novartis seeks HSE reimbursement for PMR and how the NCPE assesses it. Priya Life Science will report if an NCPE entry appears. People with PMR should not change their treatment without talking to their doctor.
Sources
- Novartis, Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR), 17 November 2026
- Novartis, Novartis receives European Commission approval for Cosentyx in polymyalgia rheumatica (PMR), 21 October 2026
- Novartis, Novartis receives positive CHMP opinion for Cosentyx in polymyalgia rheumatica (PMR), 18 September 2026
- Novartis, Cosentyx PMR data in the New England Journal of Medicine showed sustained remission vs placebo in twice as many patients, 3 June 2026
- Novartis, Novartis Cosentyx meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR), 22 October 2025
- BioPharm International, FDA Approves Cosentyx as First Anti-IL-17 Biologic for Polymyalgia Rheumatica, 17 November 2026
- ClinicalTrials.gov, Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (REPLENISH), NCT05767034, accessed 18 November 2026
- ClinicalTrials.gov, Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (REPLENISH-EXT), NCT06331312, accessed 18 November 2026
- NHS, Polymyalgia rheumatica, accessed 18 November 2026
- Novartis Ireland, Cosentyx dosing (rheumatology), with Irish reimbursement notes, accessed 18 November 2026
- National Centre for Pharmacoeconomics, Secukinumab (Cosentyx) for psoriatic arthritis, accessed 18 November 2026
- Novartis Ireland, About Novartis in Ireland and Contact, accessed 18 November 2026
Cover image: AI-generated illustration.